PHC Corporation wins prestigious award for breakthrough in live cell analysis

In October 2024, PHC Corporation, based in Chiyoda-ku, Tokyo, Japan, launched LiCellMo, a live cell metabolic analyzer designed to transform research in cellular metabolism. This innovative instrument allows for continuous, real-time monitoring of key metabolites such as glucose and lactate directly in cell cultures. By eliminating the need for periodic sampling, which can introduce contamination and disrupt the culture environment, LiCellMo provides researchers with unprecedented access to dynamic cellular data. The Biomedical Division of PHC Corporation, led by President Nobuaki Nakamura, aims to improve research methods in fields such as cancer immunology and stem cell studies. By providing minute-by-minute measurements, researchers can gain insights into previously unobservable metabolic changes, thus enhancing the quality and reproducibility of cell culture processes. The device is expected to significantly contribute to the development of more effective cell and gene therapies. In December 2024, The Analytical Scientist awarded PHC Corporation with its prestigious 2024 Innovation Award. The award recognizes LiCellMo for its technological advancements that create new avenues in analytical science, particularly in supporting novel research findings and advancing therapeutic developments. Chikara Takauo, Director of the Biomedical Division, expressed confidence that the LiCellMo will provide researchers with transformative knowledge that benefits therapeutic manufacturing processes. Overall, the launch of LiCellMo and its recognition through the award highlights the ongoing evolution in metabolic analysis technology within the biomedical research community. By paving the way for enhanced monitoring of cell metabolism, it promises to contribute to better research outcomes in critical areas like gene therapy and disease treatment, ensuring that researchers can make informed decisions based on comprehensive real-time data.